Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect

J Thorac Oncol. 2019 Jul;14(7):e145-e146. doi: 10.1016/j.jtho.2019.02.027.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Afatinib / adverse effects*
  • Aged
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Cardiotoxicity / etiology*
  • Cardiotoxicity / pathology
  • ErbB Receptors / genetics
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Mutation*
  • Prognosis
  • Protein Kinase Inhibitors / adverse effects*

Substances

  • Protein Kinase Inhibitors
  • Afatinib
  • EGFR protein, human
  • ErbB Receptors